Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Authors:
- Robert J. MotzerRMRobert J. Motzer
- Thomas E. HutsonTHThomas E. Hutson
- Piotr TomczakPTPiotr Tomczak
- M. Dror MichaelsonMMM. Dror Michaelson
- Ronald M. BukowskiRBRonald M. Bukowski
- Stéphane OudardSOStéphane Oudard
- Sylvie NegrierSNSylvie Negrier
- Cezary SzczylikCSCezary Szczylik
- Roberto PiliRPRoberto Pili
- Georg A. BjarnasonGBGeorg A. Bjarnason
- Xavier Garcia-Del-MuroXGXavier Garcia-Del-Muro
- Jeffrey A. SosmanJSJeffrey A. Sosman
Top Cited Papers
- 1 August 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (22) , 3584-3590
Abstract
Purpose: A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported. Patients and Methods: Seven hundred fifty treatment-naïve patients with metastatic clear cell RCC were randomly assigned to sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule or to IFN-α 9 MU subcutaneously thrice weekly. Overall survival was compared by two-sided log-rank and Wilcoxon tests. Progression-free survival, response, and safety end points were assessed with updated follow-up. Results: Median overall survival was greater in the sunitinib group than in the IFN-α group (26.4 v 21.8 months, respectively; hazard ratio [HR] = 0.821; 95% CI, 0.673 to 1.001; P = .051) per the primary analysis of unstratified log-rank test (P = .013 per unstratified Wilcoxon test). By stratified log-rank test, the HR was 0.818 (95% CI, 0.669 to 0.999; P = .049). Within the IFN-α group, 33% of patients received sunitinib, and 32% received other vascular endothelial growth factor–signaling inhibitors after discontinuation from the trial. Median progression-free survival was 11 months for sunitinib compared with 5 months for IFN-α (P < .001). Objective response rate was 47% for sunitinib compared with 12% for IFN-α (P < .001). The most commonly reported sunitinib-related grade 3 adverse events included hypertension (12%), fatigue (11%), diarrhea (9%), and hand-foot syndrome (9%). Conclusion: Sunitinib demonstrates longer overall survival compared with IFN-α plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC. The overall survival highlights an improved prognosis in patients with RCC in the era of targeted therapy.Keywords
This publication has 11 references indexed in Scilit:
- Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized TrialJournal of Clinical Oncology, 2008
- Sunitinib Efficacy Against Advanced Renal Cell CarcinomaJournal of Urology, 2007
- Sunitinib: From Rational Design to Clinical EfficacyJournal of Clinical Oncology, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With SunitinibJNCI: Journal of the National Cancer Institute, 2007
- Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal TumorsAnnals of Internal Medicine, 2006
- Sunitinib in Patients With Metastatic Renal Cell CarcinomaJAMA, 2006
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Modelling Survival Data in Medical Research1994